Jump to ContentJump to Main Navigation
The Lock and Key of MedicineMonoclonal Antibodies and the Transformation of Healthcare$
Users without a subscription are not able to see the full content.

Lara V Marks

Print publication date: 2015

Print ISBN-13: 9780300167733

Published to Yale Scholarship Online: January 2016

DOI: 10.12987/yale/9780300167733.001.0001

Show Summary Details
Page of

PRINTED FROM YALE SCHOLARSHIP ONLINE (www.yale.universitypressscholarship.com). (c) Copyright Yale University Press, 2017. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a monograph in YSO for personal use (for details see http://www.yale.universitypressscholarship.com/page/privacy-policy).date: 11 December 2017

Antibody Engineering

Antibody Engineering

A Renaissance for Mab Therapeutics

Chapter:
(p.159) Chapter Eight Antibody Engineering
Source:
The Lock and Key of Medicine
Author(s):

Lara V. Marks

Publisher:
Yale University Press
DOI:10.12987/yale/9780300167733.003.0008

This chapter discusses the emergence of engineered monoclonal antibodies (Mabs) in the 1990s. The failure of Centoxin to gain FDA approval prompted many in the biotechnology and pharmaceutical industry as well as the financial world to view Mab drugs as a lost cause. However, things began to change in 1994 with the approval of ReoPro. The drug signified a major engineering revolution in Mabs after the 1980s, when various competitive and complementary engineering methods began to be developed in the academic and corporate worlds. The first Mabs—known as murine Mabs—were produced by fusing myeloma tumor cells taken from mice with spleen cells derived from other mice or rats previously immunized with an antigen. While these could be made to target almost any antigen and in vast quantities, they were considered foreign by the human body, causing patients treated with murine Mabs to experience immune reactions. This also led to the rapid destruction and clearance of the Mab from the body before it could have its full therapeutic effect. Faced with these obstacles, scientists turned to genetic engineering to transform animal antibodies into human ones.

Keywords:   Mabs, monoclonal antibodies, Mab therapeutics, Mab drugs, drug development, ReoPro, antibody engineering, animal antibodies, murine Mabs, genetic engineering

Yale Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs , and if you can't find the answer there, please contact us.